Search results for: Multi-Indication Medicines

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

1 April 2019

The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by the 2018 Seventieth World…

Around The World in HTAs: Greece – Late but with an Optimistic Future

18 October 2023

…users’ private spending making up the remaining 38% (Hellenic Statistical Authority (ELSTAT), 2023).   The HTA process framework  The value assessments of medicines and medical devices are managed separately.   Assessment of medicines …

2022 Innovation Policy Prize

…medicines to approve for reimbursement, and at what price. As higher–cost medicines put increasing pressure on public health care budgets [3], the need to identify ‘fair’ prices for medicines has never been…

Spotlight on OHE: Assessing Value and Balancing Needs in Health Care

15 December 2011

…students at City University London on current issues in valuing health and international research on them. Containing spending on medicines and ensuring access Policies intended to contain and shape spending…

The Trump Administration’s US Drug Pricing Proposal – What will happen next?

12 June 2025

…and design of the US healthcare system. This complexity is multi-factorial, with its mix of public and private providers, insurers and funders, and the multiple stakeholders and intermediaries involved in…

Around The World in HTAs: The Slovak Republic – Valuing the Future

13 September 2023

…insurance reimbursement since 2011. From 2011 to 2022, an arm of the Ministry of Health (MoH) was responsible for reviewing HTA and pharmacoeconomic analysis submissions for innovative medicines. An independent…

Incorporating Multiple Criteria in HTA: Methods and Processes

1 March 2011

…health care and many other fields has given rise to ‘multiple criteria decision analysis’ (MCDA). This is defined by the authors of this monograph as ‘A set of methods and…

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

1 December 2016

…Stakeholders’ involvement in Health Technology Assessment (HTA) can take different forms. Multi-criteria decision analysis (MCDA) offers systematic ways to collect evidence on how stakeholders make trade-offs between decision criteria and…

Research Funding and Economic Growth

9 December 2011

…done and communities develop. There is an important distinction to make between economic ‘multipliers’ and ‘spillovers’ that needs to influence how policymakers approach the issue.  Multipliers occur when, for example,…